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Background. Pentoxifylline (PTX) anti-TNF properties are known to exert hepatoprotective eﬀects in various liver injury models.
The aim of this study was to investigate whether PTX has beneficial roles in the development of methionine- and choline-deficient-
(MCD-) diet-induced NAFLD SD rats in vivo and TNF-α-induced Hep3B cells in vitro. Methods. SD Rats were classified according
to diet (chow or MCD diet) and treatment (normal saline or PTX injection) over a period of 4 weeks: group I (chow + saline,
n = 4), group II (chow + PTX), group III (MCD + saline), and group IV (MCD + PTX). Hep3B cells were treated with 100 ng/ml
TNF-α (24 h) in the absence or presence of PTX (1mM). Results. PTX attenuatedMCD-diet-induced serum ALT levels and hepatic
steatosis. In real-time PCR and western blotting analysis, PTX decreased MCD-diet-induced TNF-alpha mRNA expression and
proapoptotic unfolded protein response by ER stress (GRP78, p-eIF2, ATF4, IRE1α, CHOP, and p-JNK activation) in vivo. PTX
(1mM) reduced TNF-α-induced activation of GRP78, p-eIF2, ATF4, IRE1α, and CHOP in vitro. Conclusion. PTX has beneficial
roles in the development of MCD-diet-induced steatohepatitis through partial suppression of TNF-α and ER stress.
1. Introduction
Although the proposed theory [1, 2] of pathogenesis of
nonalcoholic fatty liver disease (NAFLD) has been chal-
lenged, chronic inflammation plays a pivotal role in the
development of fatty liver disease. TNF-α and IL-6, which are
cytokines associated with inflammation, are found in higher
levels in subjects with nonalcoholic steatohepatitis (NASH)
than in those without simple NASH [3]. Consequently, a
therapeutic strategy targeting TNF-α has been attempted
to reduce fat accumulation and improve AST (aspartate
aminotransferase) and ALT (alanine aminotransferases) in
subjects with fatty liver disease [4–6]. Among the drugs
used to suppress or inhibit TNF-α expression, pentoxifylline
(PTX), a nonselective phosphodiesterase inhibitor reported
to decrease TNF-α gene transcription as well as aﬀect
multiple steps in the cytokine pathway by direct or indirect
inhibition of TNF-α, is currently used in the clinical field
for treatment of cardiovascular disease [4, 7–9]. Several pilot
studies have shown the beneficial eﬀects of pentoxifylline on
NAFLD and NASH [4, 5, 10]. The endoplasmic reticulum
and oxidative stress of the initiation and progression of
hepatic steatosis and inflammation have been implicated
under metabolic stress conditions [11]. Recently, Zhang et
al. [9] demonstrated ER stress-induced hepatic steatosis.
Based on these reports, we hypothesized that fat storage,
triggered by cytokine-mediated inflammation, could be
decreased through the alleviation of ER stress. Therefore,
we investigated whether pentoxifylline has a beneficial role
in methionine- and choline-deficient-(MCD-) diet-induced
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fatty liver disease in a rat animal model and examined
molecular pathways related to ER stress.
2. Method
2.1. Cell Culture. Human Hep3B cells were cultured in Dul-
becco’s Modified Eagle Medium (DMEM, Welgene, Daegu,
Republic of Korea) with 4.5 g/L glucose and 2mM glutamine
supplemented with 10% FBS, 1.5 g/L sodium bicarbonate,
100 IU/mL penicillin, and 100 ug/mL streptomycin. The me-
dium was changed twice a week, and the cells were main-
tained in a 37◦C incubator with 5% CO2. The cells were sub-
cultured when confluent (every 5∼7 days) using trypsin (2.5
g/L) and EDTA (1 g/L).
For the western blot analysis, the cells were plated at 3
× 105/well in 6-well plates and then treated with 100 ng/mL
TNF-α (R&D system, Minneapolis, MN) in the absence or
presence of 1mM PTX (Sigma).
2.2. Animals and Experimental Protocol. Sprague Dawley
(SD) rats (male, 220–280 g body weight) purchased from
Orient Bio Inc. (Sungnam, Republic of Korea) were ran-
domly divided into four groups (six rats per group) as
follows. Group I: chow diet plus saline injection (once/day,
i.p.); group II: chow diet plus PTX injection (50mg/kg,
once/day, i.p; PTX); group III: MCD diet plus saline
injection (once/day, i.p.); group IV: MCD diet plus PTX
injection (50mg/kg, once/day, i.p.) for four weeks. Pentoxi-
fylline (PTX) was purchased from Handock Pharmaceuticals
(Seoul, Republic of Korea), and MCD diet was purchased
from Dyets Inc. (Bethlehem, Pennsylvania). The rats were
maintained at 60 ± 5% relative humidity and 22 ± 2◦C,
with a 12-hour light/dark cycle. Blood was obtained by
cardiac puncture, and the livers were removed and weighed.
The livers were fixed in 10% formalin or snap frozen in
liquid nitrogen and then stored at −70◦C for histologic
analysis. All experimental procedures were performed under
sterile conditions and approved by the Institutional Animal
Care and Use Committee of Yonsei University College of
Medicine.
2.3. Determination of Serum and Hepatic Biochemistry Levels.
Aspartate aminotransferase (AST), alanine aminotransferase
(ALT), total cholesterol (T-CHO), and triglyceride (TG) were
quantified in serum using a commercial kit (Asanpharm
Inc., Seoul, Republic of Korea). Frozen liver tissue was
homogenized in 0.9% NaCl solution, and the homogenate
was diluted to solution of 1 : 2 chloroform:methanol. The
homogenate was mixed vigorously with vortex mixer and
centrifuged at 1,000 rpm for 20min. The upper phase was
aspirated, and then the chloroform phase was used for the
analysis of a variety of metabolite.
2.4. Histological Analysis. Fresh tissues were frozen imme-
diately after each animal was sacrificed, and the tissue was
placed in prelabeled base molds filled with embedding
medium used for frozen tissue to ensure optimal cutting
temperature (OCT). Routine frozen sections (7 μm) were
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Figure 1: Viability of Hep3B cells after treatment with TNF-α
and pentoxifylline. Hep3B cells exposed to 10, 20, 50, 100, and
200 ng/mL TNF-α for 24 hours showed a significant decrease in cell
viability, assessed by MTT. Pretreatment with 1mM pentoxifylline
for 2 and 4 h prevented TNF-α-induced Hep3B toxicity. The
bars represent percent cytotoxicity versus untreated controls. The
experiments were performed four times under identical conditions.
Results are shown as mean ± SEM. ∗∗∗P < 0.001 versus untreated
control cells; †††P < 0.001 versus 1mMpentoxifylline for 2 h; ‡‡‡P <
0.001 versus 1mM pentoxifylline for 4 h.
stained with oil-red O (Sigma, St Louis, MO). The paraﬃn-
embedded sections were stained with hematoxylin & eosin
(H-E) and Masson’s trichrome. To evaluate hepatic steatosis,
morphometric analysis was performed on two randomly
selected fields (at 200 × magnification) of each animal sec-
tion using an Olympus IX71 microscope with an Olympus
DP70 camera (Olympus Optical Company, Tokyo, Japan).
2.5. Real-Time PCR. Total RNA from liver was isolated using
Trizol Reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. The hepatic mRNA levels of
TNF-α were quantified by real-time PCR using the ABI
PRISM 7500 sequence detection system (Applied Biosystems,
Foster, CA) with TaqMan fluorogenic probes and primers
for TNF-α: forward, 5′-AAT GGC CTC CCT CAT CAG
TT-3′; reverse, 5′-CCA CTT GGT GGT TTG CTA CGA-3′.
PCR reactions and analyses were obtained using Sequence
Detector Software (Applied Biosystems, Foster, CA).
2.6. Western Blot. Homogenized liver tissues or Hep3B were
lysed in lysis buﬀer (Intron Biotechnology, Sungnam, Repub-
lic of Korea) containing 50mM Tris, pH 7.5, 150mM NaCl,
1mM EDTA, 1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS, 1 μM phenylmethylsulfonyl fluoride (PMSF),
5 μg/mL aprotinin, and 5 μg/mL leupeptin. The protein
extracts were quantified using Bradford assay (Bio-Rad, Her-
cules, CA). The protein extracts were loaded into 10% SDS-
PAGE, followed by transfer to nitrocellulose membrane (Bio-
Rad). After blocking with 5% skimmilk in 1XPBS, the mem-
branes were incubated with each specific primary antibody,
including GRP78 (Santa Cruz Biotechnology, Santa Cruz,
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Figure 2: Serum chemistry values after 4 weeks of administration with an MCD diet and pentoxifylline. There was a significant decrease in
serum triglyceride and total cholesterol in rats in the MCD plus saline (group III) and MCD plus PTX (group IV) groups relative to rats in
control group (group I). A significant increase of ALT levels in groups III and IV was observed. Results are shown as mean ± SEM. ∗∗P <
0.01, ∗∗∗P < 0.001 versus untreated control group.
CA), total and phospho-eIF2α (Cell Signaling Technology,
Danvers, MA), ATF4 (Santa Cruz), ATF6 (ABNOVA, Taipei
city, Taiwan), IRE1 (Santa Cruz), phospho-JNK (Cell sig-
naling), CHOP, and β-actin (Santa Cruz), at 4◦C overnight.
The membranes were washed with TBS-T and incubated
with peroxidase conjugated anti-rabbit IgG or anti-mouse
IgG (Santa Cruz) for one hour at room temperature.
The membrane was washed and incubated with detection
solution (GEHealthcare, Buckinghamshire, NA, UK) for one
minute and was then exposed to film. The signal intensity
for each specific band on the western blots was quantified
using National Institutes of Image J density analysis software
(version 1.20).
2.7. Statistical Analysis. Statistical analysis was performed
using PRISM (GraphPad Software Inc., San Diego, CA).
Results are expressed as mean ± SD. Statistical significance
was calculated using one-way analysis of variance (ANOVA)
with a post hoc Bonferroni multiple comparison test to assess
the diﬀerences between groups. Statistical significance was
defined as the conventional P value of < 0.05.
3. Results
3.1. Eﬀect of TNF-α and Pentoxifylline on Viability Hep3B
Cells. Hep3B cells exposed to 10, 20, 50, 100, and 200 ng/mL
TNF-α for 24 hours showed significantly decreased viability
as assessed by MTT (1.00 ± 0.02 versus 0.83 ± 0.04, 0.86 ±
0.03, 0.85 ± 0.02, 0.86 ± 0.04, 0.87 ± 0.01, P < 0.001 for all).
Compared to untreated controls, Hep3B cells treated with
1mM PTX for 24 h showed statistically increased viability
(1.00 ± 0.02 versus 1.07 ± 0.01, P < 0.05). Pretreatment with
1mM pentoxifylline for 2 (0.97± 0.03) and 4 h (0.97± 0.01)
significantly reduced TNF-α- induced Hep3B cell viability (P
< 0.001 versus 10, 20, 50, 100, and 200 ng/mL TNF-α). Based
on these results, we chose the concentrations of 100 ng/mL
TNF-α and 1mM PTX for this experiment (Figure 1).
3.2. Metabolic Eﬀects of MCD Diet and Pentoxifylline on SD
Rats. The amount of weight loss was diﬀerent between rats
given MCD plus saline (group III) and MCD plus PTX
(group IV) for four weeks: −53.6 ± 9.2 g (19.6%) and –63.4
± 10.2 g (23.4%) from their initial body weights. However,
the diﬀerence was not significant. Such degree of weight
loss is similar to previously reported data where rats were
placed on MCD diets [1–3]. In contrast, rats in the control
group gained a minimal amount of weight (4.6%) during the
study period. Liver weight was not diﬀerent among the four
groups. The proportion of liver weight to body weight was
similar between groups III and IV (Table 1).
The blood concentrations of TG, T-CHO, AST, and ALT
were analyzed using serum. Rats in groups III and IV showed
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Figure 3: Hepatic histology and triglyceride content after 4 weeks of administration with an MCD diet and pentoxifylline. The liver sections
were stained with H&E, Masson’s trichrome, and oil-red O staining (×200). The liver of MCD-diet-fed rats showed yellowish markings. Rats
administrated pentoxifylline showed the reduced yellow hepatic color and fat accumulation (a). Rats in groups III and IV have increased
hepatic triglyceride content relative to rats in the control group. There was no statistical diﬀerence between groups III and IV (b). Results are
shown as mean ± SEM. ∗∗P < 0.01 versus untreated control group.
statistically decreased serum TG and T-CHO levels relative
to rats in the control group. ALT levels were significantly
increased inMCD-fed rats (groups III & IV) compared to the
control groups, but there were no diﬀerences between groups
III and IV (Figure 2).
3.3. Hepatic Eﬀects of MCD Diet and Pentoxifylline on SD
Rats. Macroscopic and histological images of liver pathology
were obtained. Liver sections were stained with H&E,
Masson’s trichrome, and oil-red O staining. In rats fed chow
diet (groups I and II), there was no detectable fatty change
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Table 1: Metabolic eﬀects of MCD diet and pentoxifylline on SD rats.
Group Chow + saline Chow + PTX MCD + saline MCD + PTX
Initial BW (g) 269.2± 39.3 265.1± 37.6 268.4± 34.9 270.7± 39.0
Final BW (g) 402.1± 32.0 385.6± 33.5 214.8± 30.4 207.3± 32.1
Weight change (g) 132.9± 14.2 120.5± 10.5 −53.6± 9.2 −63.4± 10.2
Liver weight (g) 12.4± 1.5 11.7± 1.0 10.1± 2.8 9.8± 2.2
LW/BW (%) 3.1± 0.0 3.0± 0.0 4.7± 0.0 4.7± 0.0
LW: liver weight, BW: body weight.
in gross appearance and microscopic image as assessed
by H&E and oil-red O staining. In contrast, the liver
of MCD-diet-fed rats showed yellowish markings, typical
of steatosis. Consistent with statistically increased serum
ALT levels, extensive macrovesicular steatosis and minimal
inflammation around perisinusoidal area were present in
group III. In rats that were administrated pentoxifylline,
the intensity of yellow color as well as fat accumulation
was reduced. In addition to liver discoloration and fat
accumulation, minimal perivenular fibrosis typically seen in
NASH was found in MCD-fed rats (Figure 3(a)).
Rats in groups III and IV had increased hepatic triglyc-
eride content relative to rats in the control group (515.1
± 200.5, 375.7 ± 35.92 versus 223.6 ± 50.02mgTG/mg
protein), and significant increase was found in group III
(P < 0.01). However, there were no statistical diﬀerences
between groups III and IV (Figure 3(b)).
3.4. Eﬀect of MCD-Diet-Induced Hepatic TNF-α Expression.
The hepatic TNF-α mRNAs from the four groups were
measured using real-time PCR. Hepatic TNF-alpha gene
expression was significantly increased in the MCD diet
groups (groups III and IV) relative to the control group (1.14
± 0.15 versus 8.12 ± 0.45, 3.45 ± 0.24, P < 0.001 for both).
Administration of PTX (50mg/kg, once/day, i.p) in MCD
diet rats (group IV) significantly decreased TNF-α mRNA
expression (P < 0.001) as compared to MCD-diet-fed rats
in group III (Figure 4).
3.5. Eﬀect of Pentoxifylline on TNF-α-Induced ER Stress in
Hepatocytes and Hep3B Cells. Western blotting assay was
performed to elucidate the hypothesis that downregulation
of direct or indirect TNF-α-induced ER stress markers by
pentoxifylline would attenuate hepatosteatosis.
ER stress markers were measured in liver protein levels
in vivo. Compared to chow-diet-fed rats (group I), rats fed
MCD diet (group III) showed increased levels of GRP78,
phosphor-eIF2α, ATF4, ATF6, IRE1, p-JNK, and CHOP, with
significant increases found in ATF4, ATF6, and IRE1 (P <
0.05 for ATF6, P < 0.001 for ATF4 and IRE1). Compared
to MCD-diet-fed rats in group III, the expression of GRP78,
phosphor-eIF2α, ATF4, ATF6, IRE1, p-JNK, and CHOP was
attenuated in PTX-administered, MCD-fed rat (group IV),
significantly in GRP78, p-eIF2α, ATF4, and ATF6 (P < 0.05
for GRP78 and p-eIF2α, P < 0.01 for ATF4 and ATF6, resp.)
(Figure 5(a)).
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Figure 4: Hepatic TNF-α gene expression after 4 weeks of treatment
with an MCD diet and pentoxifylline. There was a significant
increase in liver TNF-α mRNA levels in rats fed MCD (groups III
and IV). Administration of PTX in MCD diet rats significantly
decreased the TNF-αmRNA expression. Results are shown as mean
± SEM. ∗∗∗P < 0.001 versus untreated control group. †††P < 0.001:
MCD plus saline versus MCD plus PTX group.
Hep3B cells exposed to 100 ng/mL TNF-α for 24 h
activated GRP78, phosphor-eIF2α, ATF4, IRE1, and CHOP
in vitro. Significant increases were found in phosphor-eIF2α,
ATF4, IRE1, p-JNK, and CHOP (P < 0.05 for p-eIF2α, ATF4
and P < 0.001 for IRE1, p-JNK, and CHOP). Pretreatment
with 1mM PTX for 18 and 24 h reduced TNF-α-induced ER
stress in Hep3B cells, significantly in p-eIF2α, ATF4, IRE1,
p-JNK, and CHOP (Figure 5(b)).
4. Discussion
Similar to unsatisfactory explanation for pathophysiology
of nonalcoholic fatty liver disease (NAFLD) encompass-
ing steatosis plus necroinflammation, controversy remains
regarding the eﬃcacy of therapeutic strategy targeting oxida-
tive stress and TNF-α [4, 5] in the treatment of NAFLD.
Although heterogenous results of pentoxifylline have been
reported from randomized controlled trials of NAFLD
treatments [4], consistent evidence in pentoxifylline-treated
patients regarding improved liver aminotransferase levels, its
safety of treatment for the treatment of alcohol-related liver
disease, and significant improvement on mortality suggest
pentoxifylline as a candidate for NAFLD treatment [6]. Few
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Figure 5: Eﬀect of pentoxifylline on TNF-α-induced ER stress in Hep3B cells and hepatocytes. Rats fed MCD diet (group III) showed
activated levels of GRP78, phosphor-eIF2α, ATF4, ATF6, IRE1, p-JNK, and CHOP with significance in ATF4, ATF6, and IRE1. Compared to
group III, administration of PTX in MCD diet rats (group IV) attenuated the expression of GRP78, phosphor-eIF2α, ATF4, ATF6, p-JNK,
and CHOP (a). The experiments were performed five times under identical conditions. Results are shown as mean ± SEM. ∗∗∗P < 0.001
versus untreated control group. †P < 0.05, ††P < 0.001: MCD plus saline versus MCD plus PTX group. Hep3B cells exposed to 100 ng/mL
TNF-α for 24 h activated GRP78, p-eIF2α, ATF4, ATF6, IRE1, p-JNK, and CHOP. Pretreatment of 1mM PTX for 18 and 24 h reduced
TNF-α-induced ER stress in Hep3B cells (b). The experiments were performed four times under identical conditions.
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studies have investigated the eﬀects of pentoxifylline on
inflammation-induced NAFLD animal model. In view of
these facts, our attentions were focused on the antihepato-
toxic eﬀect of pentoxifylline (PTX), a nonselective TNF-α
inhibitor, on improvement of inflammation and fat droplets
accumulation in methionine- and choline-deficient-(MCD-)
diet-induced steatohepatitis. We hypothesized that PTX may
inhibit TNF-α-induced endoplasmic reticulum (ER) stress
and reactive oxygen species (ROS) pathway, allowing for
alleviation of steatohepatitis in vitro and in vivo. Concerning
animal models used to investigate the pathogenesis or
treatment eﬃcacy of steatohepatitis characterizing human
condition, we adopted MCD-diet-induced rat steatohepati-
tis model. MCD diet depletes hepatic antioxidants, such
as GSH and S-adenosylmethionine (S-AMe), and induces
production of TNF-α and other proinflammatory cytokines
[7]. According to one study, after 26 days of MCD feeding,
serum ALT levels increased consistently, and steatohepatitis
ultimately developed [1]. In this study, the rats were fed
either chow or MCD diet for 4 weeks.
This study has two main findings. First, in accordance
with previous reports, the administration of MCD diet for
four weeks induced steatosis, inflammation and ballooning
degeneration of hepatocytes, but not pericellular fibrosis.
Endoplasmic reticulum (ER) stress was found to cause the
degradation of misfolded or unfolded proteins in the ER
through three pathways, including double-stranded RNA-
activated protein kinase—like ER-resident kinase (PERK),
inositol-requiring protein-1 (IRE), and activating transcrip-
tion factor-6 (ATF6) pathwaies [8]. Similar to previous
reports on ER stress in development of NAFLD [8, 9], MCD
diet increased hepatic TNF-α expression and activated ER
stress factors such as Bip/GRP78, p-eIF2, ATF4, ATF6, IRE1,
and CHOP. Treatment with 100 ng/mL TNF-α in vivo also
caused ER stress. The discrepancies of statistical significance
between hepatocytes acquired from MCD diet rats and
Hep3B cells on the expression of ER stress markers in the
group of TNF-α only and the groups of both TNF-α and PTX
may be attributed to nonuniform pattern of downstream of
ER stress markers, especially ATF4, CHOP, and GADD34 in
human and animal subjects with NAFLD and NASH [10].
In contrast with the human metabolic profiles of hep-
atic consequences of metabolic syndrome [12], MCD-fed
animals demonstrate weight loss associated with atrophy of
adipose tissue [2]. In this experiment, chow diet resulted
in an increase in rat weight by approximately 132.9 g, but
MCD diet resulted in a decrease in weight of approximately
53.6 g after four weeks of diet. This weight loss in the
MCD diet group led to 50.8% and 58.3% decrease in serum
triglyceride and total cholesterol level compared to the chow
diet group, with statistical significance. Compared to the
controls, MCD-induced steatohepatitis also led to 50.8%
and 233.0% increase in AST and ALT levels, with statistical
significance found only in ALT level.
Second, intraperitoneal treatment with pentoxifylline in
rats fed MCD diet decreased fat accumulation. However, the
eﬀects of PTX on either body and liver weight or serum
lipid profile and aminotransferases were not profound.
The minimal eﬀects of PTX on metabolic profiles, while
contradictory to the expected results, may be attributed to
the overwhelming eﬀect of MCD diet due to prolonged 4-
week feeding model adopted in this study. Conventional
duration of the MCD diet ranges from 2 to 3 weeks [1–3].
However, compared to MCD-fed rats, rats fed PTX showed
significantly decreased hepatocellular expression of TNF-
α mRNA. In vitro, pretreatment with 1mM PTX in the
presence of 100 ng/mL TNF-α attenuated ER stress. We have
suggested that pentoxifylline has anti-inflammatory eﬀects
against cytokine-induced steatohepatitis. Therefore, as we
and others have found, pentoxifylline might exert its main
eﬀects through alleviation on ER stress.
To summarize our data, we observed that pentoxifylline
(PTX) alleviated ER stress in TNF-α-induced cytotoxic
human hepatocarcinoma Hep3B cells in vitro and had
protective eﬀect on the development of steatohepatitis in
a methionine- and choline-deficient (MCD) diet animal
model in vivo. Further clinical studies are needed to evaluate
the use of PTX for nonalcoholic fatty liver disease.
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